Avances en inmunoterapias: linfoma de células B, trasplante renal, bronquiolitis, aterosclerosis, enfermedad inflamatoria intestinal

– BsAbs before CD19 CAR-T: full speed ahead! Blood. 2024 Jul 18;144(3):249-251.
– A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med 2024;391:122-132.
– Nirsevimab and Hospitalization for RSV Bronchiolitis. N Engl J Med 2024;391:144-154.
– Monoclonal Antibody chP3R99 Reduces Subendothelial Retention of Atherogenic Lipoproteins in Insulin-Resistant Rats: Acute Treatment Versus Long-Term Protection as an Idiotypic Vaccine for Atherosclerosis. J Am Heart Assoc. 2024 Jul 2;13(13):e032419.
– Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet? Gut, 2024; doi: 10.1136/gutjnl-2024-332919.